Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 µg b.i.d.) as an Active Control

This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe persistent asthma.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Drug: Indacaterol 300 μg; Drug: Placebo to indacaterol; Drug: Placebo to salmeterol; Drug: Salmeterol 50 μg

• Study Type: Interventional
• Enrollment (Actual): 805
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina
    • Novartis Investigator Site
  • Cordoba, Argentina
    • Novartis Investigator Site
  • Rosario, Argentina
    • Novartis Investigator Site
  • San Miguel de Tucuman, Argentina
    • Novartis Investigator Site
• Canada
  • Halifax, Canada
    • Novartis Investigator Site
  • London, Canada
    • Novartis Investigator Site
  • Mississauga, Canada
    • Novartis Investigator Site
  • Montreal, Canada
    • Novartis Investigator Site
  • Ste-Foy, Canada
    • Novartis Investigator Site
• Czech Republic
  • Brno, Czech Republic
    • Novartis Investigator Site
  • Praha, Czech Republic
    • Novartis Investigative Site
  • Praha, Czech Republic
    • Novartis Investigator Site
• France
  • Brest cedex, France
    • Novartis Investigator Site
  • Castelnau-le-Lez, France
    • Novartis Investigator Site
  • Chauny, France
    • Novartis Investigator Site
  • Paris Cedex 14, France
    • Novartis Investigator Site
  • Tarbes Cedex, France
    • Novartis Investigator Site
  • Vandoeuvre Les Nancy, France
    • Novartis Investigator Site
• Germany
  • Berlin, Germany
    • Novartis Investigator Site
  • Bochum, Germany
    • Novartis Investigator Site
  • Borstel, Germany
    • Novartis Investigator Site
  • Geesthacht, Germany
    • Novartis Investigator Site
  • Hamburg, Germany
    • Novartis Investigator Site
  • Kiel, Germany
    • Novartis Investigator Site
  • Leipzig, Germany
    • Novartis Investigator Site
  • Luebeck, Germany
    • Novartis Investigator Site
  • Mainz, Germany
    • Novartis Investigator Site
  • Marburg, Germany
    • Novartis Investigator Site
  • Neumunster, Germany
    • Novartis Investigator Site
  • Neuss, Germany
    • Novartis Investigator Site
  • Schwetzingen, Germany
    • Novartis Investigator Site
  • Wiesloch, Germany
    • Novartis Investigator Site
  • Wittem, Germany
    • Novartis Investigator Site
• Hungary
  • Debrecen, Hungary
    • Novartis Investigator Site
  • Nyiregyhaza, Hungary
    • Novartis Investigator Site
  • Sopron, Hungary
    • Novartis Investigator Site
  • Szombathely, Hungary
    • Novartis Investigator Site
  • Tatabanya, Hungary
    • Novartis Investigator Site
• Italy
  • Brescia, Italy
    • Novartis Investigator Site
  • Catania, Italy
    • Novartis Investigator Site
  • Modena, Italy
    • Novartis Investigator Site
  • Parma, Italy
    • Novartis Investigator Site
  • Pietra Ligure, Italy
    • Novartis Investigator Site
  • Pisa, Italy
    • Novartis Investigator Site
  • Terni, Italy
    • Novartis Investigator Site
  • Torino, Italy
    • Novartis Investigator Site
  • Trieste, Italy
    • Novartis Investigator Site
• Peru
  • Lima, Peru
    • Novartis Investigator Site
• Slovakia
  • Bardejov, Slovakia
    • Novartis Investigator Site
  • Bratislava, Slovakia
    • Novartis Investigator Site
  • Kosice, Slovakia
    • Novartis Investigator Site
  • Nitra, Slovakia
    • Novartis Investigator Site
  • Trencin, Slovakia
    • Novartis Investigator Site
• Spain
  • Alicante, Spain
    • Novartis Investigator Site
  • Barcelona, Spain
    • Novartis Investigator Site
  • Begonte, Spain
    • Novartis Investigator Site
  • Caceres, Spain
    • Novartis Investigator Site
  • Cádiz, Spain
    • Novartis Investigator Site
  • Granollers, Spain
    • Novartis Investigator Site
  • Hospitalet de Llobregat, Spain
    • Novartis Investigative Site
  • Hostalets de Balenyà, Spain
    • Novartis Investigator Site
  • Illescas, Spain
    • Novartis Investigator Site
  • Mataró, Spain
    • Novartis Investigator Site
  • Oviedo, Spain
    • Novartis Investigator Site
  • Sevilla, Spain
    • Novartis Investigator Site
  • Valencia, Spain
    • Novartis Investigator Site
• Turkey
  • Ankara, Turkey
    • Novartis Investigator Site
  • Istanbul, Turkey
    • Novartis Investigator Site
  • Istanbul, Turkey
    • Novartis Investigative Site
  • Izmir, Turkey
    • Novartis Investigator Site
• United States
  • Arizona
    • Glendale, Arizona, United States, 85306
      • Novartis Investigator Site
    • Phoenix, Arizona, United States, 85306
      • Novartis Investigator Site
  • California
    • Encinitas, California, United States, 92024
      • Novartis Investigator Site
    • Huntington Beach, California, United States, 92647
      • Novartis Investigator Site
    • Long Beach, California, United States, 90806
      • Novartis Investigator Site
    • Long Beach, California, United States, 90808
      • Novartis Investigator Site
    • Oakland, California, United States, 94609
      • Novartis Investigator Site x 2 sites
    • Orange, California, United States, 92868
      • Novartis Investigator Site
    • Palmdale, California, United States, 93551
      • Novartis Investigator Site
    • San Diego, California, United States, 92123
      • Novartis Investigator Site
    • San diego, California, United States, 92120
      • Novartis Investigator Site
    • Walnut Creek, California, United States, 94598
      • Novartis Investigator Site
    • los Angeles, California, United States, 90025
      • Novartis Investigator Site
  • Colorado
    • Denver, Colorado, United States, 80206
      • Novartis Investigator Site
    • Denver, Colorado, United States, 80230
      • Novartis Investigator Site
    • Englewood, Colorado, United States, 80112
      • Novartis Investigator Site
    • Lakewood, Colorado, United States, 80401
      • Novartis Investigator Site
  • Florida
    • Brandon, Florida, United States, 33511
      • Novartis Investigator Site
    • Largo, Florida, United States, 33770
      • Novartis Investigator Site
    • Miami, Florida, United States, 33143
      • Novartis Investigator Site
    • Panama City, Florida, United States, 32405
      • Novartis Investigator Site
    • Pensacola, Florida, United States, 32503
      • Novartis Investigator Site
    • Pensacola, Florida, United States, 32514
      • Novartis Investigator Site x 2 sites
    • Tamarac, Florida, United States, 33321
      • Novartis Investigator Site
  • Georgia
    • Albany, Georgia, United States, 31707
      • Novartis Investigator Site
    • Stockbridge, Georgia, United States, 30281
      • Novartis Investigator Site
  • Kansas
    • Overland Park, Kansas, United States, 66215
      • Novartis Investigator Site
    • Topeka, Kansas, United States, 66606
      • Novartis Investigator Site
    • overland Park, Kansas, United States, 66210
      • Novartis Investigator Site
  • Kentucky
    • Florence, Kentucky, United States, 41017
      • Novartis Investigator Site
  • Maryland
    • Baltimore, Maryland, United States, 21236
      • Novartis Investigator Site
    • Wheaton, Maryland, United States, 20902
      • Novartis Investigator Site
  • Massachusetts
    • North Dartmouth, Massachusetts, United States, 02747
      • Novartis Investigator Site
  • Michigan
    • Ann Arbor, Michigan, United States, 48106
      • Novartis Investigator Site
    • Ypsilanti, Michigan, United States, 48197
      • Novartis Investigator Site
  • Missouri
    • Springfield, Missouri, United States, 65807
      • Novartis Investigator Site
    • St louis, Missouri, United States, 63141
      • Novartis Investigator Site
  • Nebraska
    • Omaha, Nebraska, United States, 68130
      • Novartis Investigator Site
    • Omaha, Nebraska, United States, 68131
      • Novartis Investigator Site
  • New Jersey
    • Northfield, New Jersey, United States, 08225
      • Novartis Investigator Site
  • New York
    • Rockville Centre, New York, United States, 11570
      • Novartis Investigator Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28207
      • Novartis Investigator Site
    • High Point, North Carolina, United States, 27262
      • Novartis Investigator Site
    • Winston-Salem, North Carolina, United States, 27103
      • Novartis Investigator Site
  • Ohio
    • Cincinnati, Ohio, United States, 45252
      • Novartis Investigator Site
    • Toledo, Ohio, United States, 43617
      • Novartis Investigator Site
  • Oklahoma
    • Edmond, Oklahoma, United States, 73003
      • Novartis Investigator Site
    • Oklahoma City, Oklahoma, United States, 73120
      • Novartis Investigator Site
  • South Carolina
    • Greenville, South Carolina, United States, 29615
      • Novartis Investigator Site
  • Texas
    • Dallas, Texas, United States, 75231
      • Novartis Investigator Site
    • Houston, Texas, United States, 77024
      • Novartis Investigator Site
    • Houston, Texas, United States, 77030
      • Novartis Investigator Site
    • Houston, Texas, United States, 77054
      • Novartis Investigator Site
    • Houston, Texas, United States, 77070
      • Novartis Investigator Site
  • Washington
    • Kirkland, Washington, United States, 98034
      • Novartis Investigator Site
    • Seattle, Washington, United States, 98105
      • Novartis Investigator Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and female patients aged ≥ 12 years (or ≥ 18 years depending upon regulatory and/or Institutional Review Board/Independent Ethics Committee/Research Ethics Board [IRB/IEC/REB] approval) who have signed an informed consent form.

2. Patients with moderate to severe persistent asthma, diagnosed according to the Global Initiative for Asthma (GINA) guidelines (Updated 2006) and who additionally meet the following criteria:

   • Patients who have used treatment with a bronchodilator, either regularly or on-demand, and who had used a daily dose of at least 100 μg beclomethasone dipropionate (or equivalent) for at least 1 month prior to screening.
   • Patients whose forced expiratory volume in 1 second (FEV1) is ≥ 50% of the predicted normal value.
   • Patients with documented (in the previous 6 months) or who demonstrate (prior to randomization) a ≥ 12% and at least 200 ml increase in FEV1, after inhaling 200 μg salbutamol.

Exclusion Criteria:

1. Pregnant or nursing (lactating) women and women of child-bearing potential UNLESS they meet pre-specified definitions of post-menopausal or are using pre-specified acceptable methods of contraception.
2. Patients who have used tobacco products within the 12 month period prior to screening, or who have a smoking history of greater than 10 pack years.
3. Patients who suffer from chronic obstructive pulmonary disease (COPD) as diagnosed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (2006).
4. Patients who have had emergency room treatment for an acute asthma attack in the 6 weeks prior to screening or who have been hospitalized for an acute asthma attack in the 6 months prior to screening, or at any time between screening and Week 1.
5. Patients with diabetes Type I or those with uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or glycosylated hemoglobin (HbA1C) > 8.0% measured at screening.
6. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition or a clinically relevant laboratory abnormality that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.
7. Patients with a history of long QT syndrome, or whose QTc interval (Bazett's formula) is prolonged to > 450 ms (males) or > 470 ms (females).
8. Certain medications for asthma and allied conditions such as long-acting bronchodilators must not be used prior to screening and for a pre-specified minimum washout period.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Indacaterol 300 μg; Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.	Drug: Indacaterol 300 μg; Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).; Drug: Placebo to indacaterol; Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).; Drug: Placebo to salmeterol; Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
Experimental: Indacaterol 600 μg; Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.	Drug: Indacaterol 300 μg; Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).; Drug: Placebo to salmeterol; Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
Active Comparator: Salmeterol 50 μg; Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.	Drug: Placebo to indacaterol; Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).; Drug: Salmeterol 50 μg; Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients With at Least 1 Adverse Event During the 26 Weeks of the Study	Adverse events include asthma exacerbations. An asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with rescue oral or intravenous (IV) corticosteroids. Asthma worsening that required treatment with inhaled or nebulized short-acting β2-agonists or an increase in inhaled corticosteroids only was not considered an asthma exacerbation.	Baseline (Day 1) to end of study (Week 26)
Systolic Blood Pressure 1 Hour Post-dose at Day 1	Systolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. The analysis included baseline systolic blood pressure and forced expiratory volume in 1 second (FEV1) pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Day 1
Systolic Blood Pressure 1 Hour Post-dose at Week 12	Systolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. The analysis included baseline systolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 12
Diastolic Blood Pressure 1 Hour Post-dose at Day 1	Diastolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. Phase V Korotkoff sounds were used for determination of diastolic pressure. The analysis included baseline diastolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Day 1
Diastolic Blood Pressure 1 Hour Post-dose at Week 12	Diastolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. Phase V Korotkoff sounds were used for determination of diastolic pressure. The analysis included baseline diastolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 12
Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Day 1	The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Day 1
Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Week 12	The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 12
Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Week 21	The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 21
24 Hour Mean Heart Rate Determined From ECG Holter Monitoring at Week 12	Continuous 24 hour electrocardiography (Holter monitoring) was conducted in a subset of patients at designated study centers, and was used to calculate the mean heart rate (in beats per minute, bpm). Patients returned the Holter monitor recorder to the clinic the morning after the 24 hour recording was complete. The results of Holter monitoring were processed centrally. The analysis included baseline 24 hour mean heart rate and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 12
24 Hour Mean Heart Rate Determined From ECG Holter Monitoring at Week 26	Continuous 24 hour electrocardiography (Holter monitoring) was conducted in a subset of patients at designated study centers, and was used to calculate the mean heart rate (in beats per minute, bpm). Patients returned the Holter monitor recorder to the clinic the morning after the 24 hour recording was complete. The results of Holter monitoring were processed centrally. The analysis included baseline 24 hour mean heart rate and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 26
Serum Potassium 1 Hour Post-dose at Day 1	Serum potassium (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline serum potassium and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Day 1
Serum Potassium 1 Hour Post-dose at Week 12	Serum potassium (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline serum potassium and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 12
Blood Glucose 1 Hour Post-dose at Day 1	Blood glucose (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline blood glucose and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Day 1
Blood Glucose 1 Hour Post-dose at Week 12	Blood glucose (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline blood glucose and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.	Week 12
Percentage of Patients With Clinically Significant Asthma Exacerbations During the 26 Weeks of the Study	A clinically significant asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with systemic corticosteroids. This includes events recorded on the asthma exacerbation clinical report form (CRF) page and events recorded on the adverse events CRF page with "asthma" as a key word in the preferred term.	Baseline (Day 1) to end of study (Week 26)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at Week 12 + 1 Day, Day 85	FEV1 (in liters, L) was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Week 12, Day 85. The analysis included baseline FEV1 and FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening as covariates.	24 hours post-dose at Week 12 + 1 day, Day 85
Number of Asthma Exacerbations Per Patient (Without Imputation) During the 26 Weeks of the Study	An asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with rescue oral or intravenous (IV) corticosteroids. The number of asthma exacerbations includes events recorded on the asthma exacerbation clinical report form (CRF) page and events recorded on the adverse events CRF page with "asthma" as a key word in the preferred term.	Baseline (Day 1) to end of study (Week 26)

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: September 1, 2007
• Primary Completion (Actual): August 1, 2008
• Study Completion (Actual): August 1, 2008

Study Registration Dates

• First Submitted: September 12, 2007
• First Submitted That Met QC Criteria: September 12, 2007
• First Posted (Estimate): September 14, 2007

Study Record Updates

• Last Update Posted (Estimate): August 29, 2011
• Last Update Submitted That Met QC Criteria: August 25, 2011
• Last Verified: August 1, 2011

More Information

Terms related to this study

• Keywords: asthma; QAB149; indacaterol
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Adrenergic Agonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Salmeterol Xinafoate
• Other Study ID Numbers: CQAB149B2338